DIAGNOS Successfully Completes the Renewal of US-FDA Medical Device Establishment Registration

This section is Partnership Content suppliedThe content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire Article contentBROSSARD, Quebec, April 01, 2026 (GLOBE NEWSWIRE) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that the annual registration for its medical device establishment with the U.S. Food and Drug Administration (FDA) has been successfully completed.Sign In or Create an AccountEmail AddressContinueor View more offersArticle contentAdditionally, DIAGNOS would like to remind the reader that the legacy version of CARA, as a Medical Image Management and Processing System, remains cleared for commercialization in the USA.Article contentWe apologize, but this video has failed to load.Try refreshing your browser, ortap here to see other videos from our team.Article contentArticle contentThe future version of CARA, which incorporates many other eye-related disease detection algorithms, is in the process of obtaining applicable regulatory approvals as detailed in the press release dated January 13, 2026.Article contentTop StoriesGet the latest headlines, breaking news and columns.There was an error, please provide a valid email address.Sign UpBy signing up you consent to receive the above newsletter from Postmedia Network Inc.Thanks for signing up!A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try againInterested in more newsletters? Browse here.Article contentDIAGNOS also announces that it intends to amend the expiry date of 5,228,668 stock warrants (each a “Warrant”) issued as part of a non-brokered private placement of units initially announced on October 25, 2024, and set to expire on April 25, 2026. The amended expiry date shall be September 25, 2026. All other provisions of the Warrants, such as the Warrants exercise price of $0.40 per common share, shall remain unchanged and fully in effect during the extended exercise period.Article contentThe amendment to the Warrants remains subject to the TSX Venture Exchange acceptance as well as execution of formal documentation.Article contentAll monies quoted in this press release shall be stated and paid in lawful money of Canada.Article contentAbout DIAGNOSDIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical eye-related health problems. By leveraging Artificial Intelligence, DIAGNOS aims to provide more information to healthcare clinicians to enhance diagnostic accuracy, streamline workflows, and improve patient outcomes on a global scale.Article contentArticle contentAdditional information is available at www.diagnos.com and www.sedarplus.com.Article contentThis news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.Article contentNeither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.Article contentArticle contentArticle contentArticle contentArticle contentArticle contentFor further information, please contact: Mr. André Larente, President DIAGNOS Inc. Tel: 450-678-8882 ext. 224 alarente@diagnos.caArticle contentTrending Suncor reveals expansion plans as key oilsands mine enters its last decade Energy Terence Corcoran: Canada hates Trump but loves his economics FP Comment KPMG faces OSC allegations of blown audit in private credit collapse Finance U.S. within 'weeks' of oil shortages if war in Iran continues: Eric Nuttall Oil & Gas ‘Revoke the agreement’: Alberta-Ottawa energy pact faces pushback Energy Share this article in your social networkCommentsYou must be logged in to join the discussion or read more comments.Create an AccountSign in Join the Conversation Postmedia is committed to maintaining a lively but civil forum for discussion. Please keep comments relevant and respectful. Comments may take up to an hour to appear on the site. You will receive an email if there is a reply to your comment, an update to a thread you follow or if a user you follow comments. Visit our Community Guidelines for more information. Suncor reveals expansion plans as key oilsands mine enters its last decade Energy Terence Corcoran: Canada hates Trump but loves his economics FP Comment KPMG faces OSC allegations of blown audit in private credit collapse Finance U.S. within 'weeks' of oil shortages if war in Iran continues: Eric Nuttall Oil & Gas ‘Revoke the agreement’: Alberta-Ottawa energy pact faces pushback Energy